Executive Summary
Across these 6 NASDAQ-100 filings dated March 2, 2026, overarching themes include strategic expansions in AI/security (AITX), resilient retail operations amid headwinds (Murphy USA), board governance refreshes (CCC, Broadcom), biotech capital access (Intellia), and M&A completion in robotics (Intuitive Surgical), with 5/6 filings carrying positive sentiment versus one mixed. Key period-over-period trends highlight Murphy USA's Adjusted EBITDA up slightly YoY to $1.02B from $1.01B despite -3.0% same-store fuel volume decline and +5.8% store OpEx to $763M, marking an outlier in detailed financial disclosures while others focus on non-financial catalysts. Critical developments like Intellia's 38% ATM capacity expansion to $1.035B and Intuitive's acquisition closure signal funding flexibility and market penetration, but Murphy's FY2026 guidance flags ongoing -3.0% to -1.0% fuel volume declines. Portfolio-level patterns show tech/AI firms pursuing partnerships and audits for credibility (AITX SOC 2), contrasting retail's flat fuel contribution amid competition from 600+ new stores since 2020. Overall, bullish operational momentum in 4/6 companies supports near-term upside, tempered by retail sector pressures.
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from February 27, 2026.
Investment Signals(10)
- AITX(BULLISH)▲
New channel partner order for 2 RIO™ 360, 1 ROSA™, 3 SARA™ licenses on day one, plus SOC 2 Type 2 audit completion and $50B security market pipeline with 35+ Fortune 500 prospects, reinforcing 35-80% cost savings edge
- Murphy USA↓(BULLISH)▲
51 new stores opened in 2025 exceeding guidance, merchandise contribution $869M, Adjusted EBITDA +1% YoY to $1.02B from $1.01B, cigarette SOM up to 20% from 16% in 2019
- CCC Intelligent Solutions↓(BULLISH)▲
Appointment of sales veteran John A. Schweitzer (ex-Salesforce EVP, Informatica CRO) as independent Class II Director, enhancing revenue expertise with reconstituted Nominating Committee
- Intellia Therapeutics↓(BULLISH)▲
ATM agreement amended to expand capacity 38% to $1.035B from $750M, providing enhanced funding flexibility post prior amendments, with prompt prospectus filing mandated
- Intuitive Surgical↓(BULLISH)▲
Completed acquisition of da Vinci/Ion distribution from ab medica et al. on March 1, 2026, expanding robotics footprint in key markets via established distributors
- Murphy USA↓(NEUTRAL-BULLISH)▲
Store mix evolution targets 44% 'others' by 2030E from 32% in 2025, with kiosk share down to 4%, signaling optimized portfolio amid competitive pressures
- AITX(BULLISH)▲
In-house development of all AI analytics/software plus ISC West 2026 demos positions RAD for multi-system deployments in scaling channel ecosystem
- CCC Intelligent Solutions↓(BULLISH)▲
No family relationships or reportable transactions for new director, ensuring clean governance under Reg S-K Item 404(a)
- Murphy USA↓(BULLISH)▲
2026 guidance intact for 45-55 new stores despite fuel headwinds, with merchandise contribution up to $890-900M from $869M
- Broadcom↓(NEUTRAL)▲
Director retirement aligns with age 75 governance policy, no disagreements noted, maintaining board stability at 8 members post-2026 AGM
Risk Flags(7)
- Murphy USA/Operational↓[HIGH RISK]▼
Same-store fuel volumes -3.0% YoY, chain fuel contribution flat amid low volatility and ~600 new competitor stores within 3 miles since 2020
- Murphy USA/Cost Pressures↓[MEDIUM RISK]▼
Store OpEx +5.8% YoY to $763M, with 2026 guidance $37.0-38.0K APSM signaling ongoing inflation vs resilient merchandise growth
- Murphy USA/Guidance↓[HIGH RISK]▼
FY2026 same-store fuel volume outlook -3.0% to -1.0%, extending YoY declines and highlighting retail competitive pressures
- Intellia Therapeutics/Dilution↓[MEDIUM RISK]▼
38% ATM expansion to $1.035B increases potential share issuance risk, requiring prospectus supplement within 2 business days of March 2, 2026
- Broadcom/Governance↓[LOW RISK]▼
Director Hartenstein retirement at 2026 AGM reduces board to 8, potentially impacting experience continuity despite policy compliance
- Murphy USA/Capital Allocation↓[MEDIUM RISK]▼
2026 Capex guidance $475-525M and SG&A $240-250M amid flat EBITDA may strain free cash flow if fuel declines persist
- AITX/Disclosure[LOW RISK]▼
No specific order value or revenue impact disclosed for new partner order, limiting quantifiable pipeline conversion visibility in $50B market
Opportunities(8)
- AITX/Channel Expansion(OPPORTUNITY)◆
Immediate multi-product order validates RAD's ecosystem, with 35+ Fortune 500 pipeline and ISC West 2026 demos offering near-term order acceleration
- Murphy USA/Guidance Beat↓(OPPORTUNITY)◆
Exceeded 2025 new store target at 51, positioning for 45-55 in 2026 with merchandise up to $890-900M; trade ahead of fuel decline offset
- CCC/Board Upgrade↓(OPPORTUNITY)◆
New director Schweitzer's Salesforce/Informatica track record (IPO leadership) boosts sales strategy in intelligent solutions space
- Intellia/Funding Access↓(OPPORTUNITY)◆
$285M+ ATM uplift enables R&D acceleration in gene editing, attractive if biotech rally resumes post-prospectus filing
- Intuitive Surgical/M&A Synergy↓(OPPORTUNITY)◆
Acquisition bolsters da Vinci/Ion distribution in Europe/LatAm, potential revenue ramp without disclosed financial terms drag
- Murphy USA/Merchandise Resilience↓(OPPORTUNITY)◆
$869M contribution in 2025 supports EBITDA stability; cigarette SOM gains to 20% signal category outperformance
- AITX/Credibility Boost(OPPORTUNITY)◆
SOC 2 Type 2 audit completion de-risks enterprise adoption, differentiating in-house AI vs. manned guarding costs
- Broadcom/Board Refresh↓(OPPORTUNITY)◆
Policy-driven retirement maintains governance hygiene, opportunity for younger director addition at 2026 AGM
Sector Themes(5)
- AI/Security Scaling(BULLISH TECH THEME)◆
AITX's partner order + SOC 2 audit reflects tech push into $50B market with 35-80% savings; 2/6 filings show channel/M&A for adoption (AITX, Intuitive)
- Retail Fuel Headwinds(BEARISH RETAIL THEME)◆
Murphy USA outlier with -3% YoY volumes, +5.8% OpEx, flat contribution amid 600+ competitors; contrasts merchandise resilience
- Governance Refreshes(NEUTRAL THEME)◆
3/6 filings (CCC appt, Broadcom retire, committee changes) indicate board optimization, with independent expertise addition
- Capital Flexibility(BULLISH BIOTECH THEME)◆
Intellia's 38% ATM expansion highlights biotech funding amid 1 filing; no buybacks/dividends noted across portfolio
- Guidance Stability(MIXED THEME)◆
Murphy's detailed 2026 targets (stores 45-55, merch $890-900M) only forward data point, but flags volume risks vs. store count evolution to 2030
Watch List(7)
- AITX/ISC West 2026👁
Live RAD demos and meetings for security pros; monitor pipeline conversions from 35+ Fortune 500 prospects [Q2 2026]
Post-conference 2026 guidance for fuel -1-3%, Capex $475-525M; watch Q1 earnings for volume updates [Next quarter]
New sales expert Schweitzer onboarding; track committee effectiveness and Q1 strategy shifts [Ongoing 2026]
Mandatory supplement under Rule 424(b) within 2 business days of March 2; monitor ATM sales execution and dilution [By March 4, 2026]
Director retirement and board resize to 8; watch successor nomination for continuity [2026 Annual Meeting]
da Vinci/Ion distribution integration from ab medica acquisition; monitor Q1 procedure volumes [Q1 2026 earnings]
Evolving mix (kiosks to 4% by 2030E); track OpEx APSM vs. $37-38K guidance [FY2026]
Filing Analyses(6)
02-03-2026
Artificial Intelligence Technology Solutions, Inc. (AITX), through its subsidiary Robotic Assistance Devices, Inc. (RAD), announced a new channel partner placed an immediate first-day order for two RIO™ 360 units, one ROSA™ system, and three SARA™ software licenses, signaling strong confidence in RAD's expanding channel ecosystem and integrated autonomous security solutions. This aligns with RAD's strategy of scaling via committed multi-system deployments in the nearly $50B USD security industry, where RAD offers 35%-80% cost savings over manned guarding. RAD maintains a prospective sales pipeline with over 35 Fortune 500 companies, though no specific order value or revenue impact was disclosed.
- ·RAD has successfully completed SOC 2 Type 2 audit, validating internal controls for customer data protection.
- ·RAD invites security professionals to ISC West 2026 for live demonstrations and meetings.
- ·All RAD technologies, AI-based analytics, and software platforms are developed in-house.
02-03-2026
Murphy USA Inc. presented at the Raymond James Institutional Investor Conference in March 2026, highlighting resilient performance with 51 new stores opened in 2025 exceeding guidance, merchandise contribution of $869M, and Adjusted EBITDA of $1.02B, up slightly from $1.01B in 2024. However, fuel volumes declined with same-store YoY at -3.0% and chain fuel contribution held flat amid low volatility and competitive pressures from ~600 new stores within 3 miles since 2020, while store OpEx rose 5.8% to $763M. 2026 guidance targets 45-55 new stores but anticipates continued same-store fuel volume decline of -3.0% to -1.0%.
- ·2026 guidance: Merchandise contribution $890-900M, Retail station OpEx $37.0-38.0K APSM, SG&A $240-250M, Capex $475-525M.
- ·Projected store count evolution: 2020 18% kiosk/51% MUSA 1400/31% others; 2025 7%/32%/29%/32%; 2030E 4%/30%/22%/44%.
- ·Cigarette SOM improved to 20% in 2025 from 16% in 2019.
02-03-2026
CCC Intelligent Solutions Holdings Inc. appointed John A. Schweitzer as a Class II Director effective March 2, 2026, leveraging his extensive experience as former EVP, Sales at Salesforce (Informatica division), EVP and Chief Revenue Officer at Informatica, and senior roles at Software AG, Workday, SAP, and Oracle. The Board determined Mr. Schweitzer to be independent under applicable rules and reconstituted the Nominating and Corporate Governance Committee by appointing Teri Williams as chairperson and adding Mr. Eilam and Mr. Schweitzer, resulting in Mr. Wei no longer serving on the committee. Mr. Schweitzer will receive standard non-employee director compensation as detailed in the company's April 8, 2025 proxy statement.
- ·Mr. Schweitzer joined Salesforce in November 2025 via its acquisition of Informatica and served as EVP, Chief Revenue Officer at Informatica from March 2021, including through its IPO in November 2021.
- ·No family relationships, arrangements, or reportable transactions under Item 404(a) of Regulation S-K involving Mr. Schweitzer.
02-03-2026
Intellia Therapeutics, Inc. amended its Open Market Sale Agreement with Jefferies LLC, increasing the total value of Common Shares issuable from $750M to $1,035,316,650, representing a 38% expansion of the ATM offering capacity. The amendment updates the issuance notice reference and changes the company contact from Glen Goddard to Edward Dulac. The company must file a Prospectus Supplement within two business days of March 2, 2026.
- ·Original Sales Agreement dated March 4, 2022, previously amended February 23, 2024
- ·Prospectus Supplement to be filed pursuant to Rule 424(b) within two Business Days
- ·Governed by New York law
02-03-2026
Broadcom Inc. announced that Director Eddy W. Hartenstein will retire from the Board at the conclusion of his term during the 2026 annual meeting of stockholders, in line with the company's Corporate Governance Guidelines upon reaching age 75; the retirement is not due to any disagreement with the company. The Board size will be reduced to eight members following the Annual Meeting.
- ·Event reported on February 24, 2026; filing dated March 2, 2026
- ·Retirement pursuant to Corporate Governance Guidelines for age 75
02-03-2026
Intuitive Surgical, Inc. completed its acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates on March 1, 2026. The company issued a press release on March 2, 2026, announcing the transaction, with the press release furnished as Exhibit 99.1. No financial terms, performance metrics, or other quantitative details were disclosed in the filing.
- ·Acquisition closed on March 1, 2026; press release dated March 2, 2026
Get daily alerts with 10 investment signals, 7 risk alerts, 8 opportunities and full AI analysis of all 6 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)